Compare JZ & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JZ | HOWL |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 18.9M |
| IPO Year | 2021 | 2021 |
| Metric | JZ | HOWL |
|---|---|---|
| Price | $0.17 | $0.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 6.7M | 642.1K |
| Earning Date | 04-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.34 |
| 52 Week High | $3.35 | $2.23 |
| Indicator | JZ | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 33.27 |
| Support Level | N/A | $0.36 |
| Resistance Level | $1.04 | $0.74 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 0.72 | 17.04 |
Jianzhi Education Technology Group Co Ltd engages in developing educational content to fulfill the massive demand for high-quality, professional development training resources in China. The company and its subsidiaries VIE and VIEs generate subscription revenue through selling subscriptions to online learning platforms, higher education institutions, and other institutional customers under a B2B2C model mainly through the platform of Sentu Academy; offering subscriptions concerning educational content in mobile video packages directly to end users under a B2C model through the platforms such as Fish Learning or Light Class, etc. It has single operating segment: Educational content services and other services and IT-related solution services.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.